• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 5. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143

Introduction to 1-(2-aminopyridin-3-yl)ethan-1-ol (CAS No. 869567-91-9)

1-(2-aminopyridin-3-yl)ethan-1-ol, identified by the Chemical Abstracts Service Number (CAS No.) 869567-91-9, is a significant compound in the realm of pharmaceutical and biochemical research. This compound belongs to the aminopyridine derivatives, a class of molecules known for their diverse biological activities and utility in drug development. The structural motif of 1-(2-aminopyridin-3-yl)ethan-1-ol features a pyridine ring substituted with an amino group at the 2-position and an ethanol moiety at the 1-position, making it a versatile scaffold for further chemical modifications and biological investigations.

The aminopyridine core is a privileged structure in medicinal chemistry due to its ability to interact with various biological targets, including enzymes and receptors. The presence of the amino group at the 2-position of the pyridine ring enhances the compound's reactivity, allowing for further functionalization through processes such as condensation, alkylation, or acylation. These modifications can lead to novel derivatives with tailored pharmacological properties, making 1-(2-aminopyridin-3-yl)ethan-1-ol a valuable intermediate in synthetic chemistry.

In recent years, there has been growing interest in 1-(2-aminopyridin-3-yl)ethan-1-ol due to its potential applications in the development of therapeutic agents. One of the most promising areas of research involves its use as a precursor in the synthesis of small-molecule inhibitors targeting kinases and other enzymes involved in cancer metabolism. Kinases are critical regulators of cellular processes, and their dysregulation is often associated with tumor growth and progression. By designing molecules that selectively inhibit aberrant kinase activity, researchers aim to develop treatments that disrupt cancer cell proliferation while minimizing side effects on healthy cells.

Recent studies have highlighted the role of aminopyridine derivatives in modulating metabolic pathways relevant to cancer cells. For instance, research published in high-profile journals has demonstrated that certain 1-(2-substituted pyridinyl)ethanols can interfere with glucose metabolism by inhibiting key enzymes such as hexokinase or glyceraldehyde 3-phosphate dehydrogenase. These findings have opened up new avenues for therapeutic intervention, particularly in cases where traditional chemotherapies have shown limited efficacy.

The ethanol moiety in 1-(2-aminopyridin-3-yl)ethan-1-ol also contributes to its pharmacological potential by influencing solubility and metabolic stability. Compounds with appropriate solubility profiles are more likely to exhibit desirable pharmacokinetic properties, including better absorption, distribution, metabolism, and excretion (ADME). Additionally, the ethanol group can serve as a site for further derivatization, enabling researchers to fine-tune physicochemical properties such as lipophilicity or polar surface area.

In terms of synthetic methodologies, 1-(2-aminopyridin-3-yl)ethan-1-ol can be synthesized through various routes, including nucleophilic substitution reactions or reductive amination strategies. The choice of synthetic pathway depends on factors such as yield optimization, scalability, and purity requirements. Advanced techniques like flow chemistry have also been explored to improve reaction efficiency and reproducibility.

The pharmaceutical industry has taken note of the versatility of 1-(2-substituted pyridinyl)ethanols, including 1-(2-amino-pyridinyl)-ethyl alcohol, as key building blocks for drug candidates. Several companies are actively engaged in developing libraries of these compounds for high-throughput screening (HTS) against various disease targets. The success of these efforts hinges on robust synthetic methodologies that can produce large quantities of structurally diverse derivatives efficiently.

Beyond oncology applications, 1-(2-amino-pyridinyl)-ethyl alcohol has shown promise in other therapeutic areas such as neurology and infectious diseases. For example, some studies suggest that certain aminopyridine derivatives may modulate neurotransmitter release or inhibit pathogenic enzymes involved in bacterial infections. These findings underscore the broad utility of this chemical class and highlight the need for continued exploration.

The development of novel pharmaceuticals is an iterative process that relies heavily on interdisciplinary collaboration between chemists, biologists, and clinicians. Computational modeling techniques have become indispensable tools in this endeavor, allowing researchers to predict molecular interactions and optimize lead compounds before experimental validation. In this context, 1-(2-amino-pyridinyl)-ethyl alcohol serves as a valuable scaffold for computational studies aimed at identifying optimal pharmacophores.

Regulatory considerations also play a crucial role in bringing new drugs to market. Regulatory agencies require extensive documentation demonstrating safety and efficacy before approving a compound for therapeutic use. This includes preclinical studies involving cell-based assays and animal models followed by clinical trials involving human subjects. The synthetic accessibility and structural diversity offered by (pyridine derivative) compounds like (CAS No 86956791) facilitate rapid progression through these stages.

In conclusion, 1-(2-amino-pyridinyl)-ethyl alcohol (CAS No: 86956791) represents an exciting opportunity for innovation across multiple sectors within life sciences research pharmaceutical development continues toward precision medicine approaches tailored individual patients needs understanding complex biochemical pathways will remain central challenge driving discovery forward into future decades

• 89226-78-8(3-(2-Aminopyridin-3-yl)propan-1-ol)
• 42753-67-3(3-ethylpyridin-2-amine)
• 945589-88-8((2-amino-3-pyridyl)-phenyl-methanol)
• 843643-03-8(6-amino-a,a-dimethyl-3-Pyridinemethanol)
• 936718-00-2((1S)-1-(2-aminopyridin-3-yl)ethan-1-ol)
• 1188316-88-2((aS)-2-amino-a-ethyl-3-Pyridinemethanol)
• 23612-57-9((2-Aminopyridin-3-yl)methanol)
• 115761-90-5(3-Pyridinemethanol,2-hydrazinyl-a-methyl-)
• 954240-84-7(2-(2-aminopyridin-3-yl)ethan-1-ol)
• 1188316-93-9((aR)-2-amino-a-ethyl-3-Pyridinemethanol)